Everything drug pricing and policy, every day
And Pfizer’s take on the pharm-to-table opportunity in obesity: ‘Multiples of what we were expecting’
And Pfizer offers few new details on how the MFN deal will impact the company’s bottom line next year
My research with Tufts CEVR on drug-price announcements, published today in AJMC, assessed 150 meds over three years
And a Tufts CEVR analysis suggests that cost-effectiveness is not playing a meaningful role in government price-setting efforts
And an evolving list of all of the pricing and policy fun to be had between now and Christmas
And the 340B rebate model debate is coming to Cost Curve’s home turf: Portland
And a STAT analysis suggests that major health insurers are seeing med spending skyrocket, but a closer look at the data raises questions
And lawmaker talk of PBM reform has returned. Will action follow?
And doing the math on 340B rebate models suggests that pharma’s new approach to paying 340B discounts shouldn’t harm providers
